Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | ||||||||||
Goods sale service render cash | -16.61%2.79B | -0.98%2.2B | 11.62%1.63B | 32.29%805.18M | -2.84%3.34B | -11.68%2.22B | -10.84%1.46B | -30.71%608.63M | -24.93%3.44B | -19.51%2.51B |
Refunds of taxes and levies | -45.80%12.57M | -45.45%9.04M | -54.58%6.16M | -73.76%2.28M | -73.06%23.19M | -83.20%16.57M | -83.94%13.56M | 150.68%8.69M | 1,051.66%86.09M | 1,060.10%98.65M |
Cash received relating to other operating activities | 53.00%565.17M | 4.08%316.34M | 15.68%258.1M | -16.61%133.93M | -40.53%369.39M | -37.68%303.95M | -51.65%223.12M | -3.52%160.61M | 38.02%621.15M | 2.65%487.74M |
Cash inflows from operating activities | -9.90%3.36B | -0.66%2.52B | 11.62%1.89B | 21.01%941.39M | -9.94%3.73B | -18.05%2.54B | -22.32%1.69B | -25.79%777.93M | -17.71%4.14B | -14.04%3.1B |
Goods services cash paid | -13.48%2.51B | -7.17%1.92B | 8.07%1.56B | 23.17%696.49M | -7.09%2.9B | -8.00%2.07B | -9.75%1.44B | -38.31%565.48M | -15.13%3.12B | -20.35%2.25B |
Staff behalf paid | -4.77%420.55M | 0.15%331.27M | 5.43%237.29M | -0.65%125.43M | -1.86%441.63M | -1.81%330.78M | -4.45%225.07M | -7.33%126.25M | -25.39%450M | -27.72%336.88M |
All taxes paid | -19.39%54.73M | -19.80%50.48M | -27.77%34.33M | -13.80%16.61M | 22.10%67.9M | 30.83%62.94M | 43.18%47.53M | 11.37%19.27M | -61.25%55.61M | -24.88%48.11M |
Cash paid relating to other operating activities | -42.30%302.64M | 22.36%271.95M | 34.48%129.33M | 28.11%157.75M | 4.08%524.48M | -50.61%222.26M | -70.16%96.17M | -5.89%123.14M | -19.07%503.91M | 33.54%450.02M |
Cash outflows from operating activities | -16.45%3.29B | -4.12%2.58B | 8.21%1.96B | 19.44%996.28M | -4.77%3.94B | -12.94%2.69B | -17.28%1.81B | -30.55%834.14M | -18.15%4.13B | -16.44%3.09B |
Net cash flows from operating activities | 136.20%73.85M | 63.59%-53.85M | 41.92%-66.99M | 2.35%-54.89M | -1,954.45%-204.01M | -1,305.49%-147.88M | -1,636.86%-115.34M | 63.20%-56.21M | 179.60%11M | 113.81%12.27M |
Investing cash flow | ||||||||||
Cash received from disposal of investments | ---- | -93.60%61.25M | -93.23%61.25M | -93.03%60.21M | 8.49%670.97M | 7.63%957.12M | 4,463.38%904.19M | 2,621,154.02%863.58M | 242.66%618.44M | 152.60%889.29M |
Cash received from returns on investments | -91.59%35.18M | -29.82%35.18M | ---- | ---- | 29.05%418.16M | -5.34%50.12M | -38.10%24.65M | ---- | 707.10%324.04M | 767.53%52.95M |
Net cash received from disposal of fix assets、 intangible assets 、other long-term asset | -26.41%67.94M | -97.02%2.29M | -95.96%2.22M | -71.36%2.34M | 46.83%92.32M | 1,507.81%76.65M | 1,835.32%54.98M | 726.03%8.18M | -72.69%62.88M | 77.85%4.77M |
Net cash received from disposal of subsidiaries and other business units | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --1.56M | ---- |
Cash inflows from investing activities | -91.27%103.12M | -90.89%98.71M | -93.55%63.47M | -92.83%62.55M | 17.33%1.18B | 14.45%1.08B | 1,474.75%983.81M | 85,119.26%871.76M | 123.34%1.01B | 162.45%947.01M |
Cash paid to acquire fixed assets intangible assets and other long-term assets | 125.91%1.04B | 178.66%710.69M | 423.03%537.52M | 167.06%213.42M | 568.45%459.67M | 938.33%255.04M | 420.70%102.77M | 419.14%79.91M | -61.74%68.77M | -57.11%24.56M |
Cash paid to acquire investments | 283.02%106M | 283.02%106M | 283.02%106M | 310.26%52M | -89.49%27.68M | -84.28%27.68M | -44.65%27.68M | --12.68M | 338.70%263.22M | 134.67%176M |
Net cash paid to acquire subsidiaries and other business units | ---- | ---- | ---- | ---- | --29.28M | ---- | ---- | ---- | ---- | ---- |
Cash paid relating to other investing activities | --59.02M | --128.48M | --128.48M | ---- | ---- | ---- | ---- | 771.57%2M | ---- | --229.47K |
Cash outflows from investing activities | 132.95%1.2B | 234.33%945.17M | 491.82%772M | 180.60%265.42M | 55.62%516.63M | 40.80%282.71M | 87.05%130.44M | 505.45%94.59M | 38.48%331.99M | 51.80%200.79M |
Net cash flows from investing activities | -265.51%-1.1B | -205.65%-846.46M | -183.03%-708.53M | -126.10%-202.87M | -1.50%664.83M | 7.37%801.18M | 11,850.25%853.37M | 5,423.03%777.17M | 219.70%674.93M | 226.48%746.22M |
Financing cash flow | ||||||||||
Cash received from capital contributions | 284.43%231.85M | --25.59M | 13,295.35%23.04M | --10.29M | 101.03%60.31M | ---- | -99.43%172K | ---- | 173.89%30M | 3,046.37%30M |
-Including: Cash received from capital contributions by minority shareholders of subsidiaries | 284.43%231.85M | ---- | ---- | --10.29M | 101.03%60.31M | ---- | ---- | ---- | 173.89%30M | 3,046.37%30M |
Cash from borrowing | 61.64%3.01B | 57.12%2.33B | 2.18%1.51B | -51.81%423.32M | -23.12%1.86B | -25.34%1.48B | -11.81%1.47B | 8.29%878.43M | -10.54%2.42B | 0.70%1.99B |
Cash received relating to other financing activities | -76.33%5.45M | ---- | ---- | ---- | -19.99%23.02M | ---- | ---- | ---- | -15.51%28.77M | -97.32%10M |
Cash inflows from financing activities | 66.91%3.25B | 58.84%2.36B | 3.73%1.53B | -50.64%433.61M | -21.58%1.95B | -26.82%1.48B | -13.86%1.47B | 8.29%878.43M | -9.87%2.48B | -13.63%2.03B |
Borrowing repayment | 3.55%1.9B | -8.90%1.41B | -34.82%887.17M | -59.61%444.7M | -43.71%1.84B | -41.63%1.55B | 11.47%1.36B | 49.81%1.1B | 15.33%3.26B | 54.62%2.65B |
Dividend interest payment | 34.02%120.96M | -52.71%53.72M | -6.73%41.3M | -19.38%21.81M | -31.15%90.25M | -0.01%113.59M | -46.30%44.29M | -22.82%27.05M | -7.93%131.08M | 15.90%113.61M |
-Including:Cash payments for dividends or profit to minority shareholders | --10M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Cash payments relating to other financing activities | -66.60%23.14M | 31.28%47.4M | 43.33%42.28M | -4.90%7.25M | 53.86%69.28M | 21.30%36.11M | 16.38%29.5M | --7.62M | 19.24%45.03M | -92.80%29.77M |
Cash outflows from financing activities | 2.50%2.05B | -10.98%1.51B | -32.35%970.76M | -58.29%473.76M | -41.95%2B | -39.27%1.69B | 7.98%1.43B | 47.50%1.14B | 14.28%3.44B | 25.49%2.79B |
Net cash flows from financing activities | 2,518.65%1.2B | 502.87%848.74M | 1,313.97%558.66M | 84.40%-40.14M | 94.80%-49.75M | 72.37%-210.68M | -89.68%39.51M | -725.87%-257.39M | -275.05%-957.13M | -712.54%-762.57M |
Net cash flow | ||||||||||
Exchange rate change effecting cash and cash equivalents | 274.78%1.23M | -49.45%229.4K | 101.25%496.74K | 160.80%144.39K | -67.33%326.9K | 326.28%453.86K | 147.45%246.83K | 62.44%-237.49K | 142.37%1M | 92.20%-200.57K |
Net increase in cash and cash equivalents | -56.73%178.02M | -111.59%-51.34M | -127.82%-216.36M | -164.27%-297.76M | 252.26%411.4M | 10,442.39%443.08M | 111.18%777.79M | 465.18%463.33M | -348.30%-270.2M | -101.64%-4.28M |
Add:Begin period cash and cash equivalents | 58.70%1.11B | 58.34%1.11B | 58.70%1.11B | 58.70%1.11B | -27.83%700.81M | -27.66%702.4M | -27.83%700.81M | -27.83%700.81M | -5.84%971.01M | -5.84%971.01M |
End period cash equivalent | 16.01%1.29B | -7.39%1.06B | -39.41%895.84M | -30.04%814.44M | 58.70%1.11B | 18.49%1.15B | 10.40%1.48B | 37.91%1.16B | -27.83%700.81M | -25.23%966.72M |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
Audit Opinions | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- |
Auditor | Zhongxi Certified Public Accountants (Special General Partnership) | -- | -- | -- | Suya Jincheng Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- | -- | Suya Jincheng Certified Public Accountants Co., Ltd. (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.